ZyVersa Therapeutics' CEO, Stephen C. Glover, to Participate in the 2024 BIO International Convention
May 14, 2024 07:57 ET
|
ZyVersa Therapeutics
To learn more about ZyVersa's Inflammasome ASC Inhibitor and Renal Pipelines, schedule a one-on-one meeting on 2024 BIO International Conference's Portal.
IO Biotech Reports First Quarter 2024 Financial Results and Provides Business Highlights
May 14, 2024 07:55 ET
|
IO Biotech
Outcome of interim analysis for the overall response rate (ORR) for the first 225 patients randomized in the pivotal Phase 3 trial (IOB-013/KN-D18) of lead investigational therapeutic cancer vaccine,...
Gain Therapeutics Reports Financial Results for First Quarter 2024 and Provides Corporate Update
May 14, 2024 07:30 ET
|
Gain Therapeutics, Inc.
BETHESDA, Md., May 14, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the...
Vivos Therapeutics Schedules Release of First Quarter 2024 Financial Results and Conference Call
May 14, 2024 07:30 ET
|
Vivos Therapeutics, Inc
LITTLETON, Colo., May 14, 2024 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a leading medical device and technology company specializing in the development...
Kura Oncology Completes Enrollment in Registration-Directed Trial of Ziftomenib in NPM1-Mutant AML
May 14, 2024 07:30 ET
|
Kura Oncology, Inc.
– Company enrolls 85 patients with R/R NPM1-mutant AML in fewer than 16 months – – Topline data expected in early 2025 – – Breakthrough Therapy Designation to enable expedited review by FDA – SAN...
Anavex Life Sciences to Present at the H.C. Wainwright 2nd BioConnect Investor Conference at NASDAQ
May 14, 2024 07:30 ET
|
Anavex Life Sciences Corp.
NEW YORK, May 14, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics...
Absci Reports Business Updates and First Quarter 2024 Financial and Operating Results
May 14, 2024 07:30 ET
|
Absci Corporation
Initiated IND-enabling studies for ABS-101 in February Continuing to advance ABS-201 and ABS-301 through preclinical studies VANCOUVER, Wash. and NEW YORK, May 14, 2024 (GLOBE NEWSWIRE) --...
nCino Announces Timing of its First Quarter Fiscal Year 2025 Financial Results Conference Call
May 14, 2024 07:30 ET
|
nCino, Inc.
WILMINGTON, N.C., May 14, 2024 (GLOBE NEWSWIRE) -- nCino, Inc. (NASDAQ: NCNO), a pioneer in cloud banking for the global financial services industry, will report financial results for its first...
HealthEquity Closes Acquisition of BenefitWallet HSA Portfolio
May 14, 2024 07:30 ET
|
HealthEquity, Inc.
DRAPER, Utah, May 14, 2024 (GLOBE NEWSWIRE) -- HealthEquity, Inc. (Nasdaq: HQY) ("HealthEquity"), the leader in Health Savings Account (HSA) and consumer-directed benefits administration, is pleased...
Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2024 Financial Results
May 14, 2024 07:30 ET
|
Xilio Therapeutics, Inc.
Expect to initiate Phase 2 trial for XTX101, a tumor-activated, Fc-enhanced anti-CTLA-4, in combination with atezolizumab in patients with microsatellite stable colorectal cancer (MSS CRC) in the...